UM > MedChem > Scott
Publications
Development of a high throughput cytochrome P450-ligand binding assay Frydendall, E. and Scott, E.E. (2024) Development of a high throughput cytochrome P450-ligand binding assay J. Biol. Chem. 19:107799.
Adrenodoxin allosterically alters human cytochrome P450 11B enzymes to accelerate substrate binding and decelerate release Loomis, C.L., Im, S-C., and Scott, E.E. (2024) Adrenodoxin allosterically alters human cytochrome P450 11B enzymes to accelerate substrate binding and decelerate release RSC Chem. Biol. 5:938.
Tracking protein-protein interactions by NMR: Conformational selection in human steroidogenic cytochrome P450 CYP17A1 induced by cytochrome <em>b</em><sub>5</sub> Richard, A.M., Estrada, D.F., Flynn, L., Pochapsky, S.S., Scott, E.E., and Pochapsky, T.C. (2024) Tracking protein-protein interactions by NMR: Conformational selection in human steroidogenic cytochrome P450 CYP17A1 induced by cytochrome b5 RSC Phys. Chem. Chem. Phys. 26:16980.
An approach to selective steroidogenic cytochrome P450 haem iron ligation by steroid-derived isonitriles Richard, A.M., Wong, N.R., Harris, K., Sundar, R., Scott, E.E., and Pochapsky, T.C. (2023) An approach to selective steroidogenic cytochrome P450 haem iron ligation by steroid-derived isonitriles Commun. Chem. 6:183.
Allosteric Modulation of Cytochrome P450 Enzymes by the NADPH Cytochrome P450 Reductase FMN-containing domain Burris-Hiday, Scott, E.E. (2023) Allosteric Modulation of Cytochrome P450 Enzymes by the NADPH Cytochrome P450 Reductase FMN-containing domain J. Biol. Chem. 299:105112.
Human cytochrome P450 3A7 binding four copies of Its native substrate dehydroepiandrosterone 3-sulfate   Liu,J., Kandel, S.E., Lampe, J.N., and Scott, E.E. (2023) Human cytochrome P450 3A7 binding four copies of Its native substrate dehydroepiandrosterone 3-sulfate   J. Biol. Chem. 299:104993.
Generation of human steroidogenic cytochrome P450 enzymes for structural and functional characterization Burris-Hiday, S.D., Loomis, C.L., Richard, A.M., Scott, E.E. (2023) Generation of human steroidogenic cytochrome P450 enzymes for structural and functional characterization Meth. Enzymol. 689:3.
Pyridine-containing substrate analogs are restricted from accessing the human cytochrome P450 8B1 active site by tryptophan 281 Liu, J., Offei, S.D., Yoshimoto, F.K., Scott, E.E. (2023) Pyridine-containing substrate analogs are restricted from accessing the human cytochrome P450 8B1 active site by tryptophan 281 J. Biol. Chem. 299:103032.
Human Cytochrome P450 17A1 Structures with Metabolites of Prostate Cancer Drug Abiraterone Reveal Substrate-Binding Plasticity and a Second Binding Site Petrunak, E.M., Bart, A.G., Peng, H-W., Auchus, R.J., and Scott, E.E. (2023) Human Cytochrome P450 17A1 Structures with Metabolites of Prostate Cancer Drug Abiraterone Reveal Substrate-Binding Plasticity and a Second Binding Site J. Biol. Chem. 299(3):102999.
Four decades of CYP2B research: from protein adducts to protein structures and beyond Roberts, A.G., Stevens, J.C., Szklarz, G.D., Scott, E.E., Kumar, S., Shah, M.B., and Halpert, J.R. (2023) Four decades of CYP2B research: from protein adducts to protein structures and beyond Drug Metab. Dispos. 51:111-122.
Cytochrome P450 8B1 structure and function: supporting drug design for non-alcoholic fatty liver disease and diabetes Liu, J., Carlson, H.A., and Scott, E.E. (2022) Cytochrome P450 8B1 structure and function: supporting drug design for non-alcoholic fatty liver disease and diabetes J. Biol. Chem. 298:102344. *Selected as Editor's Pick*.
Redox partner adrenodoxin alters cytochrome P450 11B1 ligand binding and inhibition Loomis, C.L., Brixius-Anderko, S., and Scott, E.E. (2022) Redox partner adrenodoxin alters cytochrome P450 11B1 ligand binding and inhibition J. Inorg. Biochem. 235:111934.
Cytochrome P450 binding and bioactivation of tumor-targeted duocarmycin agents Bart, A.G., Morais, G., Vangala, V.R., Loadman, P.M., Pors, K. and Scott, E.E. (2022) Cytochrome P450 binding and bioactivation of tumor-targeted duocarmycin agents Drug Metab. Dispos. 50:49-57.
Effects of fluorine substitution on substrate conversion by cytochromes P450 17A1 and 21A2 Vogt, C.D., Bart, A.G., Yadav, R., Scott, E.E. and Aubé, J. (2021) Effects of fluorine substitution on substrate conversion by cytochromes P450 17A1 and 21A2 Org. Biomol. Chem 19:7664-7669.
Structural and functional insights into aldosterone synthase interaction with its redox partner protein adrenodoxin Brixius-Anderko, S. and Scott, E. E. (2021) Structural and functional insights into aldosterone synthase interaction with its redox partner protein adrenodoxin J. Biol. Chem. 296:100794.
Aldosterone synthase structure with Cushing’s Disease drug LCI699 highlights avenues for selective CYP11B drug design Brixius-Anderko, S. and Scott, E. E. (2021) Aldosterone synthase structure with Cushing’s Disease drug LCI699 highlights avenues for selective CYP11B drug design Hypertension 78:751-759.
Steroidogenic cytochrome P450 17A1 structure and function Burris-Hiday, S.B. and Scott, E.E. (2021) Steroidogenic cytochrome P450 17A1 structure and function Mol. Cell. Endocrinol. 528:11261.
Structure-based drug design of bisubstrate inhibitors of phenylethanolamine N‐Methyltransferase possessing low nanomolar affinity at both substrate binding domains Lu, J., Bart, A.G., Wu, Q., Criscione, K.R., McLeish, M.J., Scott, E.E., and Grunewald, G.L. (2020) Structure-based drug design of bisubstrate inhibitors of phenylethanolamine N‐Methyltransferase possessing low nanomolar affinity at both substrate binding domains J. Med. Chem 63:13878-13898.
Discovery of novel non-steroidal cytochrome P450 17A1 inhibitors as potential prostate cancer agents Wróbel, T. M., Rogova, O., Andersen, K. L., Yadav, R., Brixius-Anderko, S., Scott, E. E., Olsen, L., Jørgensen, F. S. and Björkling, F. (2020) Discovery of novel non-steroidal cytochrome P450 17A1 inhibitors as potential prostate cancer agents Int. J. Mol. Sci. 21:4868-4879.
Advances in the study of drug metabolism Russell, L.E., Schleiff, M.A., Gonzalez, E., Bart, A.G., Broccatelli, F., Durmus, S., Hartman, J.H., Humphreys, W.G., Lauschke, V.M., Martin, I., Nichols, C., Nwabufo, C., Prasad, B., Scott, E.E., Segall, M., Takahashi, R., Taub, M.E., and Sodhi, J..K. (2020) Advances in the study of drug metabolism Drug Metab. Rev. 295:5640-5653.
Structure of an ancestral mammalian family 1B1 cytochrome P450 with increased thermostability Bart, A. G., Harris, K. L., Gillam E. M. J., and Scott, E. E. (2020) Structure of an ancestral mammalian family 1B1 cytochrome P450 with increased thermostability J. Biol. Chem. 295:5640-5653.
CYP17A1 exhibits 17α-hydroxylase/17,20-lyase activity towards 11β-hydroxy progesterone and 11-ketoprogesterone metabolites in the C11-oxy backdoor pathway van Rooyen, D., Yadav, R., Scott, E. E. and Swart, A. C. (2020) CYP17A1 exhibits 17α-hydroxylase/17,20-lyase activity towards 11β-hydroxy progesterone and 11-ketoprogesterone metabolites in the C11-oxy backdoor pathway J. Steroid Biochem. Mol. Biol. 199:105614.
Cytochrome P450 Binding and Activation of Anticancer Duocarmycin Produgs (2020) Cytochrome P450 Binding and Activation of Anticancer Duocarmycin Produgs J. Biol. Chem. in press.
Human cytochrome P450 1A1 adapts active site for atypical nonplanar substrate Bart A. G., Takahashi R. H., Wang X., Scott E. E. (2019) Human cytochrome P450 1A1 adapts active site for atypical nonplanar substrate Drug Metab. Dispos. 48: 86-92.
Structure of human cortisol-producing cytochrome P450 11B1 bound to the breast cancer drug fadrozole provides insights for drug design Brixius-Anderko, S. and Scott, E. E. (2019) Structure of human cortisol-producing cytochrome P450 11B1 bound to the breast cancer drug fadrozole provides insights for drug design J. Biol. Chem. 294: 453-460.
Structures of human cytochrome P450 1A1 with bergamottin and erlotinib Bart, A. G. and Scott, E. E. (2018) Structures of human cytochrome P450 1A1 with bergamottin and erlotinib J. Biol. Chem. 293:19201-19210.
Endogenous insertion of non-native metalloporphyrins into human membrane cytochrome P450 enzymes Yadav, R. and Scott, E. E. (2018) Endogenous insertion of non-native metalloporphyrins into human membrane cytochrome P450 enzymes J. Biol. Chem. 293:16623-16634.
Structures of human cytochrome P450 enzymes: variations on a theme Scott, E. E. and Godamudunage, M. P. (2018) Structures of Human Cytochrome P450 Enzymes: Variations on a Theme (2018) Dioxygen-dependent Heme Enzymes Eds. Ikeda-Saito and Raven. Publisher, Royal Society of Chemistry .
Comparison of antifungal azole interactions with adult cytochrome P450 3A4 vs. neonatal cytochrome P450 3A7 Godamudunage, M. P., Grech, A. M. and Scott, E. E. (2018) Comparison of antifungal azole interactions with adult cytochrome P450 3A4 vs. neonatal cytochrome P450 3A7 Drug Metab. Dispos. 46:1329-1337.
Structure-based design of inhibitors with improved selectivity for steroidogenic cytochrome P450 17A1 over cytochrome P450 21A2 Fehl, C., Vogt, C., Yadav, R. Li, K., Scott, E. E. and Aubé, J. (2018) Structure-based design of inhibitors with improved selectivity for steroidogenic cytochrome P450 17A1 over cytochrome P450 21A2 J. Med. Chem 11:4946-4960.
Structural and functional effects of cytochrome <em>b</em><sub>5</sub> interactions with human cytochrome P450 enzymes Bart, A.G. and Scott, E.E. (2017) Structural and functional effects of cytochrome b5 interactions with human cytochrome P450 enzymes J. Biol. Chem. 20818-20833.
Structural and functional evaluation of clinically relevant inhibitors of cytochrome P450 17A1 (CYP17A1) Petrunak, E.M., Rogers, S.A., Aubé, J., and Scott, E.E. (2017) Structural and functional evaluation of clinically relevant inhibitors of cytochrome P450 17A1 (CYP17A1) Drug Metab. Dispos. 635-645.
Omega versus omega-1 hydroxylation: Cytochrome P450 4B1 sterics make the call Scott, E.E. (2017) Omega versus omega-1 hydroxylation: Cytochrome P450 4B1 sterics make the call J. Biol. Chem. 292:5622-5623.
Illuminating cytochrome P450 binding: Ru (II)-caged inhibitors of CYP17A1 Li, A., Yadav, R., White, J.K., Herroon, M.K., Callahan, B.P., Podgorski, I., Turro, C., Scott, E.E., and Kodanko, J.J. (2017) Illuminating cytochrome P450 binding: Ru (II)-caged inhibitors of CYP17A1 Commun. Chem. 53:3673-3676.
Structural insights into the function of steroidogenic cytochrome P450 17A1 Yadav, R., Petrunak, E.M., Estrada, D.F., and Scott, E.E. (2016) Structural insights into the function of steroidogenic cytochrome P450 17A1 Mol. Cell. Endocrinol. 7207:30330-30336.
Promising tools in prostate cancer research: Selective non steroidal cytochrome P450 17A1 inhibitors Bonomo, S., Hansen, C.H., Petrunak, E.M., Scott, E.E., Styrishave, B., Jorgensen, F. S., and Olsen, L. (2016) Promising tools in prostate cancer research: Selective non steroidal cytochrome P450 17A1 inhibitors Nat. Sci. Reports 6:29468-29479.
The role of protein-protein and protein-membrane interactions on P450 function Scott, E.E., Wolf, R.C., Otyepka, M., Humphreys, S.C., Reed, J.R., Henderson, C.J., McLaughlin, L.A., Paloncýová, M., Navrátilová, V., Berka, K., Anzenbacher, P., Dahal, U.P. Barnaba, C., Brozik, J.A., Jones, J.P., Estrada, D.F., Laurence, J.S., Park, J.W., and Backes, W.L. (2016) The role of protein-protein and protein-membrane interactions on P450 function Drug Metab. Dispos. 44:576-590.
Cytochrome P450 17A1 interactions with the FMN domain of its reductase as characterized by NMR Estrada, D.F., Laurence, J.S., and Scott, E.E. (2015) Cytochrome P450 17A1 interactions with the FMN domain of its reductase as characterized by NMR J. Biol. Chem. 291:3390-4003.
Structures of human steroidogenic cytochrome P450 17A1 with substrates Petrunak, E.M., DeVore, N.M., Porubsky, P.R. and Scott, E.E. (2014) Structures of human steroidogenic cytochrome P450 17A1 with substrates J. Biol. Chem. 289:32952-32964.
Human cytochrome P450 17A1 conformational selection: modulation by ligand and cytochrome <em> b </em> <sub> 5 </sub> Estrada, D.F., Skinner, A.L., Laurence, J.S., and Scott, E.E. (2014) Human cytochrome P450 conformational selection:  Modulation by ligand and cytochrome b5 J. Biol. Chem. 289:14310-14320.
Correlating structure and function of drug metabolizing enzymes: progress and ongoing challenges Johnson, E.F., Connick, J.P., Reed, J.R., Backes, W.L., Desai, M.C., Xu, L., Estrada, D.F., Laurence, J.S. and Scott, E.E. (2014) Correlating structure and function of drug metabolizing enzymes: progress and ongoing challenges Drug Metab. Dispos. 42:9-22.
Human cytochrome P450 1A1 structure and utility in understanding drug and xenobiotic metabolism Walsh, A.A., Szklarz, G.D. and Scott, E.E. (2013) Human cytochrome P450 1A1 structure and utility in understanding drug and xenobiotic metabolism J. Biol. Chem. 288:12932-12943.
Benzylmorpholine analogs as selective inhibitors of lung cytochrome P450 2A13 for the chemoprevention of lung cancer in tobacco users Blake, L.C., Roy, A., Neul, D., Schoenen, F.J., Aubé, J. and Scott, E.E. (2013) Benzylmorpholine analogs as selective inhibitors of lung cytochrome P450 2A13 for the chemoprevention of lung cancer in tobacco users Pharm. Res. 30:2290-2302.
Substrate-modulated cytochrome P450 17A1 and cytochrome b5 interactions revealed by NMR Estrada, D.F., Laurence, J.S., and Scott, E.E. (2013) Substrate-modulated cytochrome P450 17A1 and cytochrome b5 interactions revealed by NMR J. Biol. Chem. 288:17008-17018.
Evaluation of inhibition selectivity for human cytochrome P450 2A enzymes Stephens, E.S., Walsh, A.A., and Scott, E.E. (2012) Evaluation of inhibition selectivity for human cytochrome P450 2A enzymes Drug Metab. Dispos. 40:1797-802.
Cytochrome P450 17A1 structures with prostate cancer drugs abiraterone and TOK-001 DeVore, N.M. and Scott, E.E. (2012) Cytochrome P450 17A1 structures with prostate cancer drugs abiraterone and TOK-001 Nature 482:116-119.
Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) binding and access channel in human cytochrome P450 2A6 and 2A13 enzymes DeVore, N.M. and Scott, E.E. (2012) Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) binding and access channel in human cytochrome P450 2A6 and 2A13 enzymes J. Biol. Chem. 287:26576-26585.
Structural comparison of cytochromes P450 2A6, 2A13, and 2E1 with pilocarpine DeVore, N.M., Meneely, K.M., Bart, A.G., Stephens, E.S., Battaile, K.P., and Scott, E.E. (2012) Structural comparison of cytochromes P450 2A6, 2A13, and 2E1 with pilocarpine FEBS J. 279:1621-31 .
Crystal structure of histamine dehydrogenase from Nocardioides simplex Reed, T., Lushington, G.H., Xia, Y., Hirakawa, H., Mure, M., Scott, E.E., and Limburg, J. (2010) Crystal structure of histamine dehydrogenase from Nocardioides simplex J. Biol. Chem. 285:25782-25791.
Human cytochrome P450 2E1 structures with fatty acid analogs reveal a previously unobserved binding mode Porubsky, P.R., Battaile, K.P., and Scott, E.E. (2010) Human cytochrome P450 2E1 structures with fatty acid analogs reveal a previously unobserved binding mode J. Biol. Chem. 285:22282-22290.
Targeting drug metabolizing enzymes for effective chemoprevention and chemotherapy Swanson, H.I., Njar, V.C.O., Yu, Z., Castro, D.J., Gonzalez, F.J., Williams, D.E., Huang, Y., Kong, A-N.T., Doloff, J.C., Ma, J., Waxman, D.J., and Scott, E.E. (2010) Targeting drug metabolizing enzymes for effective chemoprevention and chemotherapy Drug Metab. Dispos. 38:539-544.
Crystal structure of prolyl 4-hydroxylase from Bacillus anthracis Culpepper, M.A., Scott, E.E., and Limburg, J. (2010) Crystal structure of prolyl 4-hydroxylase from Bacillus anthracis Biochemistry 49:124-133.
Key residues controlling binding of diverse ligands to human cytochrome P450 2A Enzymes DeVore, N.M., Smith, B.D., Wang, J.L., Lushington, G.H., and Scott, E.E. (2009) Key residues controlling binding of diverse ligands to human cytochrome P450 2A Enzymes Drug Metab. Dispos. 37:1319-1327.
Structures of human cytochrome P450 2E1: Insights into the binding of inhibitors and both small molecular weight and fatty acid substrates Porubsky, P.R., Meneely, K.M., and Scott, E.E. (2008) Structures of human cytochrome P450 2E1: Insights into the binding of inhibitors and both small molecular weight and fatty acid substrates J. Biol. Chem. 283:33698-33707.
Key residues controlling phenacetin metabolism by human cytochrome P450 2A enzymes DeVore, N.M., Smith, B.D., Urban, M.J., and Scott, E.E. (2008) Key residues controlling phenacetin metabolism by human cytochrome P450 2A enzymes Drug Metab. Dispos. 36:2582-2590.
Expression, purification, crystallization and preliminary X-ray studies of a proly-4-hydroxylase protein from Bacillus anthracis Miller, M.A., Scott, E.E., and Limberg, J. (2008) Expression, purification, crystallization and preliminary X-ray studies of a proly-4-hydroxylase protein from Bacillus anthracis Acta Crystallogr. F. 64:788-791.
Expression, purification and crystallization and preliminary X-ray studies of histamine dehydrogenase from Nocardiodes simplex Reed, T.M., Hirakawa, H., Mure, M., Scott, E.E., and Limberg, J. (2008) Expression, purification and crystallization and preliminary X-ray studies of histamine dehydrogenase from Nocardiodes simplex Acta Crystallogr. F. 64:785-787.
p-Dimethylaminocinnamaldehyde derivatization for colorimetric detection and HPLC-UV/Vis-MS/MS identification of indoles Porubsky, P.R., Scott, E.E., and Williams, T.D. (2008) p-Dimethylaminocinnamaldehyde derivatization for colorimetric detection and HPLC-UV/Vis-MS/MS identification of indoles Arch. Biochem. Biophys. 475:14-17.
Functional characterization of CYP2A13 polymorphisms Schlicht, K.E., Michno, N., Smith, B.D., Scott, E.E., and Murphy, S.E. (2007) Functional characterization of CYP2A13 polymorphisms Xenobiotica 37:1439-1349.
Structure of the human lung cytochrome P450 2A13 Smith B.D., Sanders J.L., Porubsky P.R., Lushington G.H., Stout C.D., and Scott, E.E. (2007) Structure of the human lung cytochrome P450 2A13 J. Biol. Chem. 282:17306-17313.
Structures of cytochrome P450 3A4 Scott E.E. and Halpert J.R. (2005) Structures of cytochrome P450 3A4 Trends in Biochem. Sci. 30:5-7.